Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Oct 2020 – Jun 2025Where it's discussed
-
X / Twitter164 posts
-
News4 articles
-
YouTube2 videos
AI synopsis
What people are saying
Numerous contributors mention the guideline update, often using terms like 'essential insight' and 'game-changing' to underline its significance. The tone of excitement and urgency in phrases like 'new recommendations to consider' indicates a strong belief in the document's potential to enhance clinical practice and patient care.
The majority of discussions reflect a supportive tone toward the guidelines, indicating general alignment with the recommendations.
Participants express a strong curiosity and enthusiasm regarding this recent update in breast cancer treatment strategies, highlighting its relevance.
While many posts simply share links, there are some that delve into related clinical implications and research trials, showing moderate engagement.
Overall, there is a consensus that the guidelines will have a significant influence on treatment practices for early breast cancer.
Abstract in brief
- This guideline emphasizes the importance of using Cyclin-Dependent Kinase 4 and 6 (CDK4/6) inhibitors alongside standard adjuvant chemotherapy for treating early-stage breast cancer in hormone receptor-positive patients.
- It highlights that these targeted therapies can improve patient outcomes and help reduce the risk of cancer recurrence.
- The update aims to provide clearer recommendations for clinicians to implement these treatments effectively, ensuring better care for patients.
Top posts
Most liked on X and Bluesky❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK 4/6 Inhibitors. Read it here⬇️ https://t.co/0VhIuReS10 @DrRFreedman | #JenniferCaswellJin | @mHassettMDMPH | #MarkSomerfield | @shgiordano https://t.co/ePRsVbH555
Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and more! #bcsm #OncoAlert Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer https://t.co/E7qvfYgI7g
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Update | @JCOOP_ASCO @OncoAlert (this update was submitted prior to the FDA approval of Ribociclib in adjuvant setting) https://t.co/k4ey58vsOz https://t.co/vZpFmEsRhg
Rapid guideline update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer - @ASCO #AdjuvantChemotherapy #ASCO #BreastCancer #Cancer #OncoDaily #Oncology #TargetedTherap https://t.co/2lgdCb6egy
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @ndenduluri1 @gary_lyman @awolff @DrSGraff #breastcancer #BreastCancerAwarenessMonth https://t.co/PdCVcuxcqS https://t.co/MaV44kUSsH
All mentions
Guidelines on CDK4/6 Inhibitors for Early Breast Cancer Treatment
Drs. Freedman and Giordano discuss the ASCO rapid guideline update on using CDK4/6 inhibitors abemaciclib and ribociclib alongside standard chemotherapy for stage II and III breast cancer. This update aims to improve…
For Primary Care: Who Needs CDK4/6 Inhibitors? ASCO Guidelines Explained (2024 Breast Cancer Update)
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights | JCO Oncology Practice https://t.co/HaaI3l8hAA
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights https://t.co/5MRL0PyjG6
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
RT @jamecancerdoc: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Upd…
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: @ASCO Rapid Guideline Update | @JCOOP_ASCO @OncoAlert (this update was submitted prior to the FDA approval of Ribociclib in adjuvant setting) https://t.co/k4ey58vsOz https://t.co/vZpFmEsRhg
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights | JCO Oncology Practice https://t.co/12pjlaVmUh
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology https://t.co/pBwosxSgpP
RT @Senology: #Documents: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhib…
RT @Senology: #Documents: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhib…
RT @Senology: #Documents: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhib…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @Senology: #Documents: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhib…
#Documents: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update https://t.co/gd2fIQyPYo - J Clin Oncol - #senology #oncology #breast #cancer
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update https://t.co/wcFoUvUX80 #Cancer
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @oncodaily: Rapid guideline update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer - @ASCO #AdjuvantChe…
RT @newsincancer: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: AS…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
Rapid guideline update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer - @ASCO #AdjuvantChemotherapy #ASCO #BreastCancer #Cancer #OncoDaily #Oncology #TargetedTherap https://t.co/2lgdCb6egy
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @Timothee_MD: @JCO_ASCO update recommendation about adjuvant use of ribociclib in early breast cancer based on the NATALEE trial ... (ht…
RT @Timothee_MD: @JCO_ASCO update recommendation about adjuvant use of ribociclib in early breast cancer based on the NATALEE trial ... (ht…
@JCO_ASCO update recommendation about adjuvant use of ribociclib in early breast cancer based on the NATALEE trial ... (https://t.co/C6TZvbjcxA) Check out an alternate interpretation of the results we discussed with @VPrasadMDMPH here
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology https://t.co/wC7fzKydUc
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @DFCI_BreastOnc: ❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK…
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
❗️New @ASCO Rapid Guideline Update on Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer — #CDK 4/6 Inhibitors. Read it here⬇️ https://t.co/0VhIuReS10 @DrRFreedman | #JenniferCaswellJin | @mHassettMDMPH | #MarkSomerfield | @shgiordano https://t.co/ePRsVbH555
https://t.co/bb37t2OzwY Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology https://t.co/bb37t2OzwY
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
https://t.co/JvxZXJpXJh
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update https://t.co/aD3VfDJsYU
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update https://t.co/alVvqVzrMo
RT @dr_yakupergun: Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
RT @rsm2800: 2021 @ASCO guideline update addressing role of adjuvant abemaciclib + endocrine Rx: Selection of Optimal Adjuvant Chemotherapy…
RT @rsm2800: 2021 @ASCO guideline update addressing role of adjuvant abemaciclib + endocrine Rx: Selection of Optimal Adjuvant Chemotherapy…
RT @rsm2800: 2021 @ASCO guideline update addressing role of adjuvant abemaciclib + endocrine Rx: Selection of Optimal Adjuvant Chemotherapy…
2021 @ASCO guideline update addressing role of adjuvant abemaciclib + endocrine Rx: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer https://t.co/dYh63WiaSJ
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/VekCVaBMra
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/AZZ0oU39Ct #Oncology
RT @ASCO_pubs: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer - a new @ASCO guideline update https…
RT @Links_Medicus: ASCO Guideline Update: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer – via @JC…
RT @ASCO_pubs: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer - a new @ASCO guideline update https…
RT @Links_Medicus: ASCO Guideline Update: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer – via @JC…
ASCO Guideline Update: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer – via @JCO_ASCO https://t.co/scTCV76l4t
RT @qgorgas: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/7i…
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/IXlvHIfSZl
RT @qgorgas: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/7i…
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/7iPjhbJ9pS
RT @SarahCannonDocs: Check out the new @ASCO guidelines for Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breas…
RT @SarahCannonDocs: Check out the new @ASCO guidelines for Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breas…
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update https://t.co/Cn1lGDCZVD
RT @SarahCannonDocs: Check out the new @ASCO guidelines for Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breas…
RT @SarahCannonDocs: Check out the new @ASCO guidelines for Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breas…
RT @SarahCannonDocs: Check out the new @ASCO guidelines for Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breas…
Check out the new @ASCO guidelines for Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer, coauthored by Sarah Cannon Cancer Institute at @HCAMidwest's @DrSGraff @JCO_ASCO https://t.co/wYyV0fbYvl
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol #cancer #epidemiology https://t.co/yPh537b9dz
RT @nacho_pelaez: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update | Journal…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology https://t.co/eDY3aW60cg
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @jamecancerdoc: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @n…
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: @ASCO @ASCO_pubs @OncoAlert @ndenduluri1 @gary_lyman @awolff @DrSGraff #breastcancer #BreastCancerAwarenessMonth https://t.co/PdCVcuxcqS https://t.co/MaV44kUSsH
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
RT @DrSGraff: Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and…
Newest #Guideline update from @ASCO with stellar co-authors @ndenduluri1 @gary_lyman @DrAmyComander @awolff @DrRFreedman and more! #bcsm #OncoAlert Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer https://t.co/E7qvfYgI7g